Alfarol 1.0 µg — Competitive Intelligence Brief

Alfarol 1.0 µg (Alfarol 1.0 µg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin D analog. Area: Endocrinology / Metabolic disorders.

marketed Vitamin D analog Vitamin D receptor (VDR) Endocrinology / Metabolic disorders Small molecule

Target snapshot

Alfarol 1.0 µg (Alfarol 1.0 µg) — Eli Lilly and Company. Alfarol is an active vitamin D analog that binds to the vitamin D receptor to regulate calcium and phosphate homeostasis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Alfarol 1.0 µg TARGET	Alfarol 1.0 µg	Eli Lilly and Company	marketed	Vitamin D analog	Vitamin D receptor (VDR)
Dovonex	CALCIPOTRIENE		marketed	Vitamin D Analog [EPC]	Vitamin D3 receptor	1993-01-01
calcipotriene + clobetasol propionate	calcipotriene + clobetasol propionate	Leon Kircik, M.D.	marketed	Topical combination therapy (vitamin D analog + corticosteroid)	Vitamin D receptor (VDR) and glucocorticoid receptor (GR)
Calcipotriene + Betamethasone Dipropionate	Calcipotriene + Betamethasone Dipropionate	Odense University Hospital	marketed	Vitamin D analog + Corticosteroid combination	Vitamin D receptor (VDR) and Glucocorticoid receptor (GR)
doxercalciferol capsules, Hectorol® capsules	doxercalciferol capsules, Hectorol® capsules	Genzyme, a Sanofi Company	marketed	Vitamin D analog	Vitamin D receptor (VDR)
Calcitriol (Rocaltrol®)	Calcitriol (Rocaltrol®)	Joslin Diabetes Center	marketed	Vitamin D analog	Vitamin D receptor (VDR)
Calcipotriene/betamethasone	Calcipotriene/betamethasone	Derm Research, PLLC	marketed	Vitamin D analog / Corticosteroid combination	Vitamin D receptor (VDR) / Glucocorticoid receptor (GR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2026-05-26 — Dovonex · 8629128 · Formulation · US
• 2028-05-07 — Dovonex · 8263580 · Formulation · US

Sponsor landscape (Vitamin D analog class)

1. LEO Pharma · 2 drugs in this class
2. Genzyme, a Sanofi Company · 2 drugs in this class
3. National Cancer Institute, Naples · 2 drugs in this class
4. OPKO Health, Inc. · 2 drugs in this class
5. Joslin Diabetes Center · 1 drug in this class
6. Kyowa Kirin, Inc. · 1 drug in this class
7. Maimónides Biomedical Research Institute of Córdoba · 1 drug in this class
8. Shanghai Jiao Tong University Affiliated Sixth People's Hospital · 1 drug in this class
9. Shiraz University of Medical Sciences · 1 drug in this class
10. St. Justine's Hospital · 1 drug in this class